

Curriculum Vitae

Personal Information		
Title	Dr.	
Name	Joyce Wing Yan Mak	
Degree	PhD	
Country	Hong Kong	-TEOM
Affiliation	The Chinese University of Hong Kong	
E-mail	wingyanmak(at)cuhk.edu.hk	

Educational Background

MBBS, University of Hong Kong	
MRCP (UK), Member of the Royal College of Physicians	
FHKCP, Fellow of Hong Kong College of Physicians	
FHKAM (Medicine), Fellow of Hong Kong Academy of Medicine	
PhD in Medical Science (The Chinese University of Hong Kong)	
FRCP (London), Fellow of Royal College of London	

Professional Career

Associate Consultant, Department of Medicine and Therapeutics, Prince of Wales Hospital

Honorary Clinical Assistant Professor, Department of Medicine and Therapeutics, The Chinese University of Hong Kong President, Hong Kong IBD Society

Editorial Board Member, Alimentary Pharmacology and Therapeutics

Research Field

Inflammatory Bowel Disease, Gut microbiota

Main Scientific Publications

- 1. Mak WY, Mak OS, Lee CK, Tang W, Leung WK, Wong MTL, et al. Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study. J Crohns Colitis. 2018;12(12):1392-8
- Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380-9.
- <u>3.</u> <u>Mak JWY</u>, Tang W, Yip TCF, Ran ZH, Wei SC, Ahuja V, et al. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. Aliment Pharmacol Ther. 2019;50(11-12):1195-203.
- <u>4.</u> <u>Mak JWY</u>, So J, Tang W, Yip TCF, Leung WK, Li M, et al. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study. Scand J Gastroenterol. 2020;55(3):279-86.
- <u>5.</u> <u>Mak JWY</u>, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644-5.
- <u>Mak JWY</u>, Weng MT, Wei SC, Ng SC. Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan. J Gastroenterol Hepatol. 2021;36(1):171-3.
- <u>7.</u> <u>Mak JWY</u>, Lok Tung Ho C, Wong K, Cheng TY, Yip TCF, Leung WK, et al. Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry. J Crohns Colitis. 2021;15(3):401-8.
- Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in res limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1076-88. Epub 2020/11/13. doi: 10.1016/S2468-1253(20)30299-5. PubMed PMID: 33181087.
- 9. Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1089-100.
- <u>10.</u> Ho JCL, <u>Mak JWY</u>, Yip TCF, Lam HM, Cheng TY, Lam TO, et al. Risk of alanine aminotransferase flare in patients with previous hepatitis B virus exposure on biological modifier therapies-A population-based study. Liver Int. 2023;43: 588–598.